<DOC>
	<DOCNO>NCT01244139</DOCNO>
	<brief_summary>The main purpose study evaluate safety , tolerability , pharmacokinetic profile two intravenous infusion BIIB033 administer two week apart subject MS . Approximately 42 MS subject plan enrol study 7 separate group ( i.e. , 6 subject per group ) . Each subsequent group administer high dose BIIB033 . Before high dose group allow start , Drug Safety Review Committee review safety data previous group enrol , well data another study BIIB033 administer healthy volunteer ( 215HV101 ) .</brief_summary>
	<brief_title>Safety Study BIIB033 Subjects With Multiple Sclerosis</brief_title>
	<detailed_description>BIIB033 protein act certain type brain cell block function another protein call LINGO-1 . It believe LINGO-1 one reason nerve brain patient MS repair well . It think BIIB033 may improve MS repair damage nerve tissue . LINGO-1 also present brain healthy people . Subjects take part 215MS101 study 28 week . This include 4-week screening period , 2 week treatment period 2 dos BIIB033 give , post-dosing safety follow period 22 week ( depend dose cohort ) . The study test vary individual visit may include : medical history evaluation , height weight assessment , physical examination , neurological examination , vital sign assessment ( pulse , respiratory rate , blood pressure , temperature ) , MS performance score , electrocardiogram , cardiac monitoring , routine blood urine test , drug concentration test blood , hepatitis HIV test , blood clotting test , brain MRI scan , lumbar puncture , drug abuse screen pregnancy test .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Give informed consnet Aged 18 60 year Have relapse remit MS secondary progressive MS EDSS score 1 6 inclusive Body mass index 18 30 kg/m2 Commitment use effective contraception 6 month last dose study drug Treatment interferon beta glatiramer acetate allow continue study long initiation treatment least 3 month dose stable . Key Primary progressive MS Any significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , allergic anaphylactic reaction major disease Clinically significant lab value screen outside normal range Clinically significant ECG abnormality Contraindication MRI scan lumbar puncture Plans undergo elective surgery study An MS relapse resolve within 30 day screen History postive test result Hepatitis B , C HIV Serious infection within 3 month prior Day 1 Treatment MS medication within 12 month prior Day 1 : natalizumab , daclizumab , azathioprine , methotrexate , iV immunoglobulin , plasmapheresis mycophenolate motefil Prior treatment total lymphoid irradiation , T cell Tcell receptor vaccination , alemtuzumab , mitoxantone , cyclophosphamide , rituximab , fingolimod .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>BIIB033</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>anti-LINGO-1 antibody</keyword>
	<keyword>Relapsing Remitting MS</keyword>
	<keyword>remyelination</keyword>
	<keyword>myelin repair</keyword>
	<keyword>Multiple ascend dose</keyword>
	<keyword>Secondary progessive MS</keyword>
</DOC>